Lemborexant: An adjuvant in difficult-to-control diabetes?

Area of Science:

• Neuroendocrinology
• Metabolic Disorders
• Pharmacology

Background:

• The brain plays a crucial role in the development and progression of diabetes.
• Central nervous system-acting drugs, including bromocriptine and antipsychotics, can impact glycemic control.
• Existing treatments for diabetes may not be sufficient for all patients, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To introduce lemborexant, a dual orexin receptor antagonist (DORA).
• To hypothesize the potential utility of lemborexant as an adjunctive treatment for difficult-to-control diabetes.
• To identify specific patient populations who might benefit from lemborexant, including those with insomnia, hyperglycemia, and appetite dysregulation.

Main Methods:

• This article is a descriptive review and hypothesis-based proposal.
• It discusses the mechanism of action of lemborexant as a DORA.
• It reviews existing knowledge on the brain's role in diabetes and the effects of CNS-acting drugs on glycemic control.

Main Results:

• Lemborexant's dual orexin receptor antagonism suggests a potential influence on metabolic pathways.
• The drug's effects on sleep and appetite regulation may indirectly benefit glycemic control.
• The hypothesis posits that lemborexant could be beneficial in managing complex diabetes cases.

Conclusions:

• Lemborexant presents a novel therapeutic possibility for managing challenging diabetes cases.
• Its potential adjunctive role warrants investigation in individuals experiencing insomnia, high fasting glucose, and diabetes distress.
• Further clinical studies are essential to validate the efficacy and safety of lemborexant in diabetes management.